ArticleCell communication and signaling : CCS2026
SIRT6 cooperates with KDM5C to transcriptionally silence MICAL2 and inhibit tumorigenesis in pancreatic cancer.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPancreatic cancer is one of the most lethal malignancies, characterized by rapid progression, poor prognosis, and high mortality. Sirtuin 6 (SIRT6), a histone deacetylase, has been implicated in tumor suppression; however, its precise molecular mechanisms in pancreatic cancer progression and cancer stem cells (CSCs) regulation remain unclear.
methodsPancreatic cancer cells were subjected to gain- and loss-of-function of SIRT6 and lysine demethylase 5 C (KDM5C) to investigate their roles in tumor progression. Protein interactions were analyzed using co-immunoprecipitation and GST pull-down assays. Genome-wide transcriptional and chromatin occupancy analyses were performed using RNA sequencing and chromatin immunoprecipitation sequencing to identify downstream targets of the SIRT6/KDM5C complex. Gene expression changes and signaling alterations were validated by RT–qPCR and western blotting. Functional assays, including EdU incorporation, tumor sphere formation, wound-healing, and transwell assays, were conducted to evaluate cell proliferation, stemness, and metastatic potential. Clinical relevance was assessed using public datasets and immunohistochemical analysis of patient samples. In vivo tumorigenesis was evaluated using xenograft mouse models.
resultsWe report that SIRT6 interacts with KDM5C and that the expression of both proteins is downregulated in pancreatic cancer. Whole-genome analysis of the SIRT6/KDM5C complex revealed a series of target genes including MICAL2. Further studies demonstrated that the SIRT6/KDM5C complex binds to the promoter of MICAL2 to repress its transcription. Additionally, we found that SIRT6/KDM5C regulates target genes to suppress pancreatic cancer cell proliferation, metastasis, and stemness. In vivo experiments indicated that the absence of SIRT6/KDM5C promoted tumor xenograft growth in mice.
conclusionsOur findings demonstrate that the SIRT6/KDM5C complex acts as a critical regulator of pancreatic cancer progression by transcriptionally repressing MICAL2. This study highlights SIRT6 and KDM5C as potential biomarkers and therapeutic targets for pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.